This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
3. The Eisai STING agonist E7766 leads to tumor eradication in 9/10 treated animals in a syngeneic model when injected…
molecule
1 year ago ●
1 min read
4. The ARIAD/Takeda EGFR exon 20 insertion mutant (EGFRex20ins) inhibitor TAK-788 is a Breakthrough Therapy for patients with advanced non-small…
molecule
1 year ago ●
1 min read
5. The Millenium/Takeda SUMO-activating enzyme (SAE) inhibitor TAK-981 is a mechanism-based inhibitor that covalently forms a SUMO substrate-inhibitor adduct that…
molecule
1 year ago ●
1 min read
6. The Bristol Myers Squibb (BMS) HPK1 kinase inhibitor, “compound 24” is an oral tool compound intended for cancer immunotherapy,…
molecule
1 year ago ●
1 min read
7. The Arbutus PD-L1 inhibitor ARB-272572 is a preclinical molecule that potently induces PD-L1 dimerization and internalization and demonstrates oral…
molecule
1 year ago ●
1 min read
8. The EicOsis oral soluble epoxide hydrolase (sEH) inhibitor, EC5026, is a compound currently intended as a non-opioid analgesic and…
molecule
1 year ago ●
1 min read
Load More
